US pharmaceutical company Organon (NYSE: OGN) has announced the official market launch of its single-tablet compound preparation Liptruzet (ezetimibe, torvastatin) in China for the treatment of hypercholesterolemia and homozygous familial hypercholesterolemia (HoFH). The launch marks a significant step in addressing the lipid management needs of Chinese patients.
Liptruzet combines the well-established lipid-lowering ingredients ezetimibe and torvastatin, offering enhanced lipid-lowering intensity and improved treatment compliance. Clinical studies have demonstrated that the combination of ezetimibe and atorvastatin can significantly reduce low-density lipoprotein cholesterol (LDL-C) levels by up to 54%, with a safety profile comparable to taking atorvastatin alone. The drug received marketing approval in China in 2023, setting the stage for its commercial availability.- Flcube.com
